Dova Pharmaceuticals, Inc. (DOVA) Forecasted to Post Q1 2018 Earnings of ($0.42) Per Share

Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) – Research analysts at Jefferies Group issued their Q1 2018 EPS estimates for Dova Pharmaceuticals in a research note issued to investors on Thursday. Jefferies Group analyst E. Yang forecasts that the company will earn ($0.42) per share for the quarter. Jefferies Group currently has a “Buy” rating and a $30.00 target price on the stock. Jefferies Group also issued estimates for Dova Pharmaceuticals’ Q2 2018 earnings at ($0.45) EPS, Q3 2018 earnings at ($0.46) EPS and Q4 2018 earnings at ($0.53) EPS.

Dova Pharmaceuticals (NASDAQ:DOVA) last released its quarterly earnings data on Thursday, November 9th. The company reported ($0.38) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.30) by ($0.08). During the same quarter in the prior year, the business posted ($0.41) EPS.

COPYRIGHT VIOLATION WARNING: “Dova Pharmaceuticals, Inc. (DOVA) Forecasted to Post Q1 2018 Earnings of ($0.42) Per Share” was first published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of US and international copyright and trademark laws. The original version of this piece of content can be read at https://ledgergazette.com/2017/11/13/dova-pharmaceuticals-inc-dova-forecasted-to-post-q1-2018-earnings-of-0-42-per-share.html.

Other analysts also recently issued research reports about the stock. J P Morgan Chase & Co assumed coverage on shares of Dova Pharmaceuticals in a report on Monday, July 24th. They issued an “overweight” rating and a $35.00 price objective for the company. Leerink Swann upgraded shares of Dova Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $32.00 price objective for the company in a report on Tuesday, September 26th. Finally, Zacks Investment Research upgraded shares of Dova Pharmaceuticals from a “hold” rating to a “buy” rating and set a $31.00 price objective for the company in a report on Wednesday, October 11th.

Shares of Dova Pharmaceuticals (NASDAQ DOVA) opened at $23.13 on Monday. Dova Pharmaceuticals has a 1-year low of $16.98 and a 1-year high of $29.99.

In other news, Director Paul B. Manning purchased 25,870 shares of the business’s stock in a transaction dated Wednesday, August 16th. The stock was acquired at an average price of $22.30 per share, for a total transaction of $576,901.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Steven M. Goldman purchased 20,169 shares of the business’s stock in a transaction dated Tuesday, August 15th. The shares were purchased at an average price of $22.23 per share, with a total value of $448,356.87. Following the acquisition, the director now directly owns 81,158 shares in the company, valued at $1,804,142.34. The disclosure for this purchase can be found here.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Laurion Capital Management LP acquired a new stake in shares of Dova Pharmaceuticals during the 2nd quarter worth approximately $223,000. Bank of New York Mellon Corp acquired a new stake in shares of Dova Pharmaceuticals during the 3rd quarter worth approximately $340,000. JPMorgan Chase & Co. acquired a new stake in shares of Dova Pharmaceuticals during the 2nd quarter worth approximately $382,000. Vanguard Group Inc. acquired a new stake in shares of Dova Pharmaceuticals during the 2nd quarter worth approximately $390,000. Finally, Goldman Sachs Group Inc. acquired a new stake in shares of Dova Pharmaceuticals during the 2nd quarter worth approximately $493,000. Institutional investors and hedge funds own 23.67% of the company’s stock.

About Dova Pharmaceuticals

Dova Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is focused on acquiring, developing and commercializing drug candidates. The Company’s initial focus is on thrombocytopenia, a disorder characterized by a low blood platelet count. The Company is developing avatrombopag for treatment of thrombocytopenia in patients with chronic liver disease (CLD).

Earnings History and Estimates for Dova Pharmaceuticals (NASDAQ:DOVA)

Receive News & Ratings for Dova Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply